================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13E-3
RULE 13e-3 TRANSACTION STATEMENT
UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3)
HEMOSOL INC.
------------------------------------------------------------------------
(Name of the Issuer)
HEMOSOL INC.
MDS INC.
MDS LABORATORY SERVICES INC.
------------------------------------------------------------------------
(Names of Persons Filing Statement)
COMMON SHARES
------------------------------------------------------------------------
(Title of Class of Securities)
42369K102
------------------------------------------------------------------------
(CUSIP Number of Class of Securities)
LEE D. HARTWELL PETER E. BRENT BRADLEY G. LEGGE
HEMOSOL INC. MDS INC. MDS LABORATORY SERVICES INC.
2585 MEADOWPINE BOULEVARD 100 INTERNATIONAL BOULEVARD 100 INTERNATIONAL BOULEVARD
MISSISSAUGA, ONTARIO TORONTO, ONTARIO TORONTO, ONTARIO
CANADA L5N 8H9 CANADA M9W 6J6 CANADA M9W 6J6
905-286-6200 416-675-6777 416-675-6777
------------------------------------------------------------------------
(Name, Address and Telephone Numbers of Person Authorized to
Receive Notices and Communications on Behalf of the Persons Filing Statement)
Copy of communications to:
JEFFREY NADLER, ESQ. CHRISTOPHER W. MORGAN, ESQ.
WEIL, GOTSHAL & MANGES LLP SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
767 FIFTH AVENUE 222 BAY STREET, SUITE 1750
NEW YORK, NEW YORK 10153 TORONTO, ONTARIO
212-310-8000 CANADA M5K 1J5
416-777-4700
This Statement is filed in connection with:
a. /__/ The filing of solicitation materials or an information statement
subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities
Exchange Act of 1934.
b. /__/ The filing of a registration statement under the Securities Act of
1933.
c. /__/ A tender offer.
d. /_X_/ None of the above.
Check the following box if the soliciting material or information statement
referred to in checking box (a) are preliminary copies: /__/
Check the following box if the filing is a final amendment reporting the results
of the transaction: /__/
CALCULATION OF FILING FEE
=====================================================================================================
Transaction Valuation* Amount of Filing Fee**
- -----------------------------------------------------------------------------------------------------
$3,478,219.04 $696.00
=====================================================================================================
* Estimated solely for purposes of computing the filing fee. The transaction
valuation was based on the product of (i) the 7% equity interest in Hemosol
being acquired by MDS pursuant to the Arrangement described herein (equal to
3,930,191 shares based on 56,145,582 Hemosol common shares outstanding as of
March 10, 2004), and (ii) $0.885, the average of the high and low prices
reported for Hemosol common shares on the Nasdaq National Market on March 17,
2004.
** The amount of the filing fee, calculated in accordance with Rule 0-11(b) of
the Securities Exchange Act of 1934, equals 1/50 of 1% of the transaction
valuation.
/_X_/ Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing with which the offsetting fee was
previously paid. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
Amount Previously Paid: $696.00 Form or Registration No.: Rule 13E-3
Transaction Statement on Schedule 13E-3 Filing Party: Hemosol Inc., MDS Inc. and
MDS Laboratory Services Inc. Date Filed: March 19, 2004
This Amendment No. 3 ("Amendment No. 3") is being filed by (i) Hemosol Inc.
("Hemosol"), a corporation existing under the Business Corporations Act
(Ontario), as amended (the "OBCA"), (ii) MDS Inc. ("MDS"), a corporation
existing under the OBCA, and (iii) MDS Laboratory Services Inc. ("MDS Subco"
and, together with Hemosol and MDS, the "Filing Persons"), a corporation
existing under the OBCA and a wholly-owned subsidiary of MDS, and amends the
Rule 13e-3 Transaction Statement on Schedule 13E-3 (as so amended by Amendment
No. 1, Amendment No. 2 and this Amendment No. 3, the "Transaction Statement")
filed pursuant to Section 13(e) of the Securities Exchange Act of 1934, as
amended, by the Filing Persons on March 19, 2004 and amended by Amendment No. 1
on April 5, 2004 and Amendment No. 2 on April 19, 2004.
The Transaction Statement relates to a proposed arrangement involving
Hemosol, its securityholders and MDS, upon the terms and conditions provided for
in the Arrangement Agreement, attached as Exhibit (d)(i) to the Rule 13e-3
Transaction Statement on Schedule 13E-3 filed by the Filing Persons on March 19,
2004.
ITEM 16. EXHIBITS.
Regulation M-A
Item 1016
(d)(iv) Form of Blood Products Security Agreements
(d)(xviii) Form of New Hemosol MOU
(d)(xxi) Form of Partnership Interest Transfer Agreement
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: April 29, 2004
HEMOSOL INC.
By: /s/ David Bell
--------------------------------------
Name: David Bell
Title: Vice President, Drug Discovery
MDS INC.
By: /s/ James A.H. Garner
--------------------------------------
Name: James A.H. Garner
Title: Executive Vice President, and
Chief Financial Officer
MDS LABORATORY SERVICES INC.
By: /s/ Bradley G. Legge
--------------------------------------
Name: Bradley G. Legge
Title: Director
EXHIBIT INDEX
EXHIBIT DESCRIPTION
- ------- -----------
(d)(iv) Form of Blood Products Security Agreements
(d)(xviii) Form of New Hemosol MOU
(d)(xxi) Form of Partnership Interest Transfer Agreement